Blood protein clues could personalize breast cancer care

NCT ID NCT02393833

Terminated Knowledge-focused Sponsor: ETOP IBCSG Partners Foundation Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study investigates whether levels of certain blood proteins—VEGF, soluble HER2, and VCAM-1—change over time in women with hormone-insensitive breast cancer. It compares women who receive maintenance chemotherapy with those who do not, and also looks at whether these protein levels differ between women whose cancer returns and those who stay cancer-free. The goal is to find markers that could help doctors tailor breast cancer treatments to each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Blood sample collection for protein analysis
What this could lead to: If certain blood proteins are linked to treatment response or recurrence, doctors might use them to personalize breast cancer therapy.
What could go wrong: This is an observational substudy, so it cannot prove cause and effect. The findings may not lead to immediate changes in treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Study site

Ibadan, Nigeria
Study site

Lima, Peru
Istituto Europeo di Oncologia (IEO

Milan, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.